Clinomics Inc
KOSDAQ:352770
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Clinomics Inc
Research & Development
Clinomics Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Clinomics Inc
KOSDAQ:352770
|
Research & Development
-₩1.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Research & Development
-₩208B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-14%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Research & Development
-₩69.9B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Research & Development
-₩17.9B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Research & Development
-₩28.4B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
-31%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Research & Development
-₩93B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
Clinomics Inc
Glance View
Clinomics, Inc. conducts bio and medical research activities. The company is headquartered in Ulsan, Ulsan. The company went IPO on 2020-12-04. The firm's main businesses are multi-omics-based service business and liquid biopsy-based cancer diagnosis and screening business. The multi-omics-based service business provides products and services that predict physical characteristics and diseases based on genome diagnosis and tests, and provides early diagnosis services for major diseases such as cancer based on multi-omics. The liquid biopsy-based cancer diagnosis and screening business sells medical devices that diagnose patients by extracting blood cells and deoxyribonucleic acid (DNA), and diagnostic and monitoring kits for cancer mutations in patients. The company is also develops products that diagnoses cancer early with blood.
See Also
What is Clinomics Inc's Research & Development?
Research & Development
-1.6B
KRW
Based on the financial report for Dec 31, 2024, Clinomics Inc's Research & Development amounts to -1.6B KRW.
What is Clinomics Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-4%
Over the last year, the Research & Development growth was -88%. The average annual Research & Development growth rates for Clinomics Inc have been 4% over the past three years , -4% over the past five years .
